237 related articles for article (PubMed ID: 20031730)
1. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries.
Lasala JM; Cox DA; Dobies D; Baran K; Bachinsky WB; Rogers EW; Breall JA; Lewis DH; Song A; Starzyk RM; Mascioli SR; Dawkins KD; Baim DS;
Circ Cardiovasc Interv; 2009 Aug; 2(4):285-93. PubMed ID: 20031730
[TBL] [Abstract][Full Text] [Related]
2. Usage patterns and 2-year outcomes with the TAXUS express stent: results of the US ARRIVE 1 registry.
Lasala JM; Cox DA; Dobies D; Muhlestein JB; Katopodis JN; Revtyak G; Baim DS;
Catheter Cardiovasc Interv; 2008 Oct; 72(4):433-45. PubMed ID: 18814217
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry.
Jensen LO; Tilsted HH; Thayssen P; Kaltoft A; Maeng M; Lassen JF; Hansen KN; Madsen M; Ravkilde J; Johnsen SP; Sørensen HT; Thuesen L
EuroIntervention; 2010 Apr; 5(8):898-905. PubMed ID: 20542774
[TBL] [Abstract][Full Text] [Related]
4. Long-term paclitaxel-eluting stent outcomes in elderly patients.
Forman DE; Cox DA; Ellis SG; Lasala JM; Ormiston JA; Stone GW; Turco MA; Wei JY; Joshi AA; Dawkins KD; Baim DS
Circ Cardiovasc Interv; 2009 Jun; 2(3):178-87. PubMed ID: 20031714
[TBL] [Abstract][Full Text] [Related]
5. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
[TBL] [Abstract][Full Text] [Related]
6. In-hospital complications and long-term outcomes of the paclitaxel drug-eluting stent in acute ST-elevation myocardial infarction: a real-world experience from a high-volume medical center.
Shammas NW; Shammas GA; Hahn A; Jerin M; Dippel EJ; Winter M
Cardiovasc Revasc Med; 2009; 10(3):151-5. PubMed ID: 19595395
[TBL] [Abstract][Full Text] [Related]
7. Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study.
Beijk MA; Klomp M; van Geloven N; Koch KT; Henriques JP; Baan J; Vis MM; Tijssen JG; Piek JJ; de Winter RJ
Catheter Cardiovasc Interv; 2011 Aug; 78(2):189-95. PubMed ID: 21542109
[TBL] [Abstract][Full Text] [Related]
8. Outcomes after differential use of drug-eluting stents in diabetic patients: 1-year results from the DES.DE (Drug-Eluting Stent.DEutschland) registry.
Akin I; Bufe A; Eckardt L; Reinecke H; Richardt G; Kuck KH; Senges J; Schneider S; Nienaber CA;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):50-7. PubMed ID: 20578192
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
11. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos).
de la Torre-Hernández JM; Alfonso F; Hernández F; Elizaga J; Sanmartin M; Pinar E; Lozano I; Vazquez JM; Botas J; Perez de Prado A; Hernández JM; Sanchis J; Nodar JM; Gomez-Jaume A; Larman M; Diarte JA; Rodríguez-Collado J; Rumoroso JR; Lopez-Minguez JR; Mauri J;
J Am Coll Cardiol; 2008 Mar; 51(10):986-90. PubMed ID: 18325436
[TBL] [Abstract][Full Text] [Related]
12. Effect of length and diameter of drug-eluting stents versus bare-metal stents on late outcomes.
Applegate RJ; Sacrinty MT; Kutcher MA; Santos RM; Gandhi SK; Little WC
Circ Cardiovasc Interv; 2009 Feb; 2(1):35-42. PubMed ID: 20031691
[TBL] [Abstract][Full Text] [Related]
13. Long-term clinical outcomes and stent thrombosis of sirolimus-eluting versus bare metal stents in patients with end-stage renal disease: results of Korean multicenter angioplasty team (KOMATE) Registry.
Kim BK; Oh S; Jeon DW; Yang JY; Kim JS; Park S; Choi D; Jang Y; Hong BK; Kwon HM; Lee SW; Goh CW; Kwon K; Ryu SK;
J Interv Cardiol; 2009 Oct; 22(5):411-9. PubMed ID: 19702679
[TBL] [Abstract][Full Text] [Related]
14. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
[TBL] [Abstract][Full Text] [Related]
15. Complete versus incomplete revascularization in patients with multivessel disease undergoing percutaneous coronary intervention with drug-eluting stents.
Tamburino C; Angiolillo DJ; Capranzano P; Dimopoulos K; La Manna A; Barbagallo R; Tagliareni F; Mangiafico S; Guzman LA; Galassi AR; Bass TA
Catheter Cardiovasc Interv; 2008 Oct; 72(4):448-56. PubMed ID: 18814218
[TBL] [Abstract][Full Text] [Related]
16. Off-label use and the spectre of drug-eluting stent thrombosis.
Cook S; Wenaweser P
Circ Cardiovasc Interv; 2009 Aug; 2(4):273-6. PubMed ID: 20031728
[No Abstract] [Full Text] [Related]
17. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program.
Brilakis ES; Lasala JM; Cox DA; Berger PB; Bowman TS; Starzyk RM; Dawkins KD
JACC Cardiovasc Interv; 2010 Jul; 3(7):742-50. PubMed ID: 20650436
[TBL] [Abstract][Full Text] [Related]
18. Drug-eluting stents are associated with similar cardiovascular outcomes when compared to bare metal stents in the setting of acute myocardial infarction.
Slottow TL; Steinberg DH; Roy P; Javaid A; Buch AN; Okabe T; Xue Z; Smith K; Torguson R; Pichard AD; Satler LF; Suddath WO; Kent KM; Waksman R
Cardiovasc Revasc Med; 2008; 9(1):24-8. PubMed ID: 18206634
[TBL] [Abstract][Full Text] [Related]
19. Multivessel drug-eluting stenting and impact of diabetes mellitus--a report from the EVENT registry.
Novack V; Tsyvine D; Cohen DJ; Pencina M; Dubin J; Dehghani H; Kleiman NS; Cutlip DE
Catheter Cardiovasc Interv; 2009 Jun; 73(7):874-80. PubMed ID: 19180665
[TBL] [Abstract][Full Text] [Related]
20. Stent thrombosis in randomized clinical trials of drug-eluting stents.
Mauri L; Hsieh WH; Massaro JM; Ho KK; D'Agostino R; Cutlip DE
N Engl J Med; 2007 Mar; 356(10):1020-9. PubMed ID: 17296821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
